$110,011.26 research Payment -- Vertex Pharmaceuticals to Dr. Jessica Moore
Vertex Pharmaceuticals invests over $110,000 in genetics research for Xarelto
This page provides a detailed analysis of a $110,011.26 research payment from Vertex Pharmaceuticals to Dr. Jessica Moore. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $110,011.26 |
| Payment Type | research |
| Payment Nature | Research |
| Pharmaceutical Company | Vertex Pharmaceuticals |
| Physician | Dr. Jessica Moore |
| NPI Number | 1393278169 |
| Physician Specialty | Genetics |
| Location | City, LA |
| Date of Payment | 2025-09-22 |
| Related Drug/Device | Xarelto |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Vertex Pharmaceuticals made a $110.0K research payment to Jessica Moore, a Genetics specialist in City, LA. The payment was associated with Xarelto. Vertex Pharmaceuticals made a significant payment of $110,011.26 to Dr. Jessica Moore for research purposes. The payment is associated with Xarelto, a drug commonly used for anticoagulation. This payment falls under the 'research' category, indicating support for clinical trials or studies.
Patient Guidance: What This Payment Means for You
If you are involved in a clinical trial funded by a pharmaceutical company, ensure you understand the study's objectives and your role. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for research are common in the pharmaceutical industry, but a $110,011.26 payment to a genetics specialist for a drug typically used in cardiology or hematology warrants further context.
Regulatory Context: Sunshine Act Requirements
Payments made to physicians for research must be reported under the Open Payments program to ensure transparency in financial relationships between the industry and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- research-funding
- drug-development
- genetics-research
- xarelto
- vertex-pharmaceuticals
Understanding research Payments
Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.
Frequently Asked Questions About This Payment
What was this $110.0K payment for?
This was a research payment of $110.0K from Vertex Pharmaceuticals to Jessica Moore, categorized as "Research". It was associated with Xarelto. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Jessica Moore accept pharmaceutical money?
Yes, Jessica Moore received this $110.0K payment from Vertex Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Jessica Moore's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this research payment?
A research payment of $110.0K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Genetics?
To compare this payment against Genetics averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Genetics physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Jessica Moore's relationship with Vertex Pharmaceuticals?
The payment amount is substantial, suggesting a significant research project. This $110.0K research payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Genetics?
The payment date is in the future (2025-09-22), which is unusual for reported payments.
What should patients do after learning about this payment?
If you are involved in a clinical trial funded by a pharmaceutical company, ensure you understand the study's objectives and your role.
What else should I know about this research payment?
The drug Xarelto is typically prescribed by cardiologists and hematologists, not genetics specialists.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.